Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment Birinci basamak alektinib tedavisi alan alk mutasyonu pozitif akciğer kanseri hastalarının klinik özelliklerinin değerlendirilmesi


Creative Commons License

Hizal M., Bilgin B., Şendur M. A., Yücel Ş., KAHRAMAN S., EROL C., ...More

Tuberkuloz ve Toraks, vol.69, no.3, pp.321-327, 2021 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.5578/tt.20219704
  • Journal Name: Tuberkuloz ve Toraks
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.321-327
  • Keywords: Alectinib, ALK mutation, Clinical features, Lung cancer
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

© 2021, Ankara University. All rights reserved.Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment Introduction: Lung cancer is the most common cancer type and the leading cause of cancer-related mortality worldwide. The positivity rate of the anaplastic lymphoma kinase (ALK) mutation in non-small cell lung cancer (NSCLC) patients has been reported as 3-7%. This study aimed to investigate the pathological, clinical and demographic characteristics of ALK-mutant NSCLC patients who received first-line alectinib as a tyrosine kinase inhibitor in two different centers. Materials and Methods: The study was performed at the Medical Oncology Departments of Ankara City Hospital and Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital. Patients diagnosed with ALK-mutant NSCLC and received alectinib treatment as a first-line tyrosine kinase inhibitor were enrolled to study and retrospectively analyzed. Results: A total of 38 patients (15 males, 23 females) were included in the study. Median age was 56.5. 55.3% of the patients were non-smokers. All of the patients had adenocarcinoma histology. Thirty-four patients (89.5%) were metastatic. Brain metastasis was detected in 44.7% of the patients. Thirty-three patients (86.8%) were using alectinib in first-line treatment. The remaining five patients were seen to have received at least one course of chemotherapy before. The objective response rate was 78.9% with alectinib treatment. The percentage of the patients who experienced at least one side effect was 34.2% and serious side effects were 7.9%. After median 9.5 months follow-up, median progression-free survival (PFS) was not achieved. 24-month PFS was 67% and 24-month overall survival was 84%. Conclusion: Our results were compatible with previous studies in terms of the clinical, pathological and demographic features of the patients with ALK mutation. We observed that the majority of patients were non-smokers, relatively young, and female patients. The objective response rate and survival results were similar with phase 3 studies.